Anatomy & Physiology
Mini Review
Volume 1 Issue 1 - 2015
The Left Atrial Appendage in Health and Disease
Philippa J Howlett*, Nikunj R Shah and Michael Mahmoudi
Faculty of Health and Medical Sciences, University of Surrey, United Kingdom
Received: July 14, 2015 | Published: July 23, 2015
*Corresponding author: Philippa Howlett, Faculty of Health and Medical Sciences, University of Surrey, United Kingdom, Tel: 00 44 7971 168838; Email:
Citation: Howlett PJ, Shah NR, Mahmoudi M (2015) The Left Atrial Appendage in Health and Disease. MOJ Anat Physiol 1(1): 00004 DOI: 10.15406/mojap.2015.01.00004


Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmiaand results in significant morbidity and mortality. The left atrial appendage (LAA), a small embryonic remnant of the left atrium (LA), has been shown to play a key role in the pathophysiology of AF-related stroke and thromboembolism. As a consequence the LAA, in spite of its meagre size, has been described as ‘our most lethal human attachment’. Despite being a recognised harbinger of disease, the LAA has also been shown to play an important role in health. This review seeks to address our current understanding of this vital structure in both health and disease states.

Keywords: Left atrial appendage; Thrombus; Atrial fibrillation; Stroke; Thromboembolism


AF: Atrial Fibrillation; LAA: Left Atrial Appendage; LA: Left Atrium; ANP: Atrial Natriuretic Peptide; TOE:  Trans Oesophageal Echocardiography


Atrial fibrillation (AF) affects 2% of the general population rising with age to affect over 10% of octogenarians [1]. Importantly AF has been predicted to increase in prevalence by three-fold by 2050 [2]. This arrhythmia is by no means benign since it confers a five-fold risk of stroke and thromboembolism and independently results in a two-fold risk of excess mortality [3]. Although formerly a somewhat neglected structure, the left atrial appendage (LAA) has been found to be a key player in stroke secondary to AF. Accordingly the LAA has in recent times been proposed as a potential therapeutic target.

Figure 1: Thrombus identified with in the left atrial appendage during TOE.

LAA anatomy
The LAA is a remnant of the embryonic left atrium (LA), which is formed during the third week of gestation. The LA itself develops later from the pulmonary veins [4]. The LAA, an outpunching of the LA, is a long, tubular structure lying in the left atrioventricular groove between the left upper pulmonary vein and the left ventricle. It comprises a single layer of endothelium and is trabeculated with underlying pectinate muscles lining the cavity. The LAA varies considerably in size from 16-51mm in length, 10-40mm in diameter and 0.77-19.27cm3 in volume [5,6]. The LAA also appears to differ in morphology with distinct variants including the ‘chicken wing’, ‘cactus’, ‘windsock’ and ‘cauliflower’ being described in 48%, 30%, 19% and 3% of cases respectively [7].

LAA Physiology
It has become increasingly apparent that the LAA has not only specific anatomical, but also, physiological properties. Like the LA, the LAA is a dynamic structure and plays a number of mechanical roles throughout the cardiac cycle. It serves as a reservoir during left ventricular systole, a conduit during early diastole, provides an active pump function in late diastole and its elasticity enforces backward flow to refill in early systole [8]. The LAA also been shown to maintain intravascular volume status through activation of stretch receptors located within its body. These afferent signals play a role in fluid haemostasis and control of heart rate in response to changes in LA pressure. In support of this, one study demonstrated that 30% of all cardiac atrial natriuretic peptide (ANP) was found within the LAA [9]. Furthermore in the healthy human heart, ANP concentration in the LAA is present in 40-times the concentration of the rest of the LA [10]. The significance of the LAA in fluid balance has been reinforced in humans after clamping of the LAA during cardiac surgery yielded increased LA and left ventricular filling pressures [8]. Animal studies have also shown that by removing the LAA, reduction of both LA compliance and LA function occurs [11]. Notably, a dramatic reduction in cardiac output, of nearly 50%, was witnessed in guinea pigs following ligation of the LAA. This finding was attributed to the contractile function of the LAA [12]. Conversely, distension of the LAA in a dog model was found to increase diuresis as well as sodium excretion and heart rate [13].

The LAA in disease
The most notable association between the LAA and disease is in the context of AF. In this setting, reduced contractility and stasis of the LAA occur, resulting in thrombus formation and thereafter the potentially catastrophic consequences of embolisation. In individuals with non-valvular AF, 90% of thrombi have been identified within the LAA; (Figure 1) [14]. Additionally it has been observed that up to 14% of patients have thrombus identifiable in the LAA within 3 days of AF onset [15]. It is these observations which have led to the LAA being termed ‘our most lethal human attachment [16]. Remodelling of the LAA in subjects with AF has been observed with chamber enlargement and decreased pectinate muscle volume [17]. Typical histological appearances include endocardial thickening, fibrosis and myocyte hypertrophy [18]. A reduced LAA peak flow velocity studied during transoesophageal echocardiography (TOE) is established to be an independent and powerful predictor of thromboembolic risk [19]. Likewise LAA morphology has been proposed as another marker of thromboembolism with the ‘cauliflower’ LAA conferring the highest risk of thrombus. In contrast patients with a ‘chicken-wing’ appearance LAA have lowest risk of embolism [7].

Similar to the LA, the LAA has been shown to increase in size in patients with a history of hypertension when compared with controls. This was also associated with a reduction in emptying velocities as demonstrated during TOE [20].         

Likewise it appears that the LAA also plays a dynamic role in the setting of left ventricular dysfunction. Firstly left ventricular impairment results in a 10-fold increase in LAA ANP concentration [10]. Furthermore, another study indicated that after successful heart failure therapy, LAA function improved significantly. It was also noted that, after treatment, LAA size reduced markedly more than LA size, demonstrating relatively increased compliance [21].

The LAA as a therapeutic target
Since the LAA has been documented to be a major culprit of thromboembolism in AF it has also been proposed as a potential therapeutic target through LAA occlusion or ligation. This treatment option is of considerable interest given the well-documented bleeding risk of anticoagulants and the significant proportion of patients who are intolerant of anticoagulation therapy [22]. To date both surgical and transcatheter LAA exclusion have been investigated with encouraging results, although trials have been criticised both for their small sample size and lack of randomisation in the majority. Recently published long-term data from the PROTECT-AF trial, randomising patients to transcatheter LAA ligation or warfarin, suggests in fact that LAA ligation may be superior to warfarin for prevention of stroke, systemic embolisation and all-cause mortality [23].


In summary the LAA plays a vital role in the pathogenesis of stroke secondary to AF. Furthermore from the available evidence it is clear that the LAA is not a redundant structure in the absence of disease. Despite outcomes suggesting that surgical and transcatheter LAA exclusion may be an alternative to conventional stroke prevention therapy, interference with the mechanical and neurohumoral functions of the LAA may result in, as yet unaccounted for, clinical sequelae. These potential consequences merit further evaluation in future trials.


PJH is the primary author with NRS contributing to the manuscript. MM proof-read the manuscript.


  1. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, et al. (2012) Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 14(11): 1553-1559.
  2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, et al. (2006) Secular trends in incidence of strialfibrillarion in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114(2): 119-125.
  3. Wolf PA, Dawber TR, Thomas HE J, Kannel WB (1978) Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 28(10): 973-977.
  4. Sherif HM (2013) The developing pulmonary veins and left atrium: implications for ablation strategy for atrial fibrillation. Eur J Cardiothorac Surg 44(5): 792-799.
  5. Su P, McCarthy KP, Ho SY (2008) Occluding the left atrial appendage: anatomical considerations. Heart 94(9): 1166-1170.
  6. Ernst G, Stöllberger C, Abzieher F, Veit-Dirscherl W, Bonner E,et al. (1995) Morphology of the left atrial appendage. Anat Rec 242(4): 553-561.
  7. Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, et al. (2012) Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from the Multicenter Study. J Am Coll Cardiol 60(6): 531-538.
  8. Tabata T, Oki T, Yamada H, Iuchi A, Ito S, et al. (1998) Role of left atrial appendage in left atrial reservoir function as evaluated by left atrial appendage clamping during cardiac surgery. Am J Cardiol 81(3): 327-332.
  9. Chapeau C, Gutkowska J, Schiller PW, Milne RW, Thibault G, et al. (1985) Localisation of immunoreactive synthetic atrial natriuretic factor (ANF) in the heart of various animal species. J Histochem Cytochem 33(6): 541-550.
  10. Rodeheffer RJ, Naruse M, Atkinson JB, Naruse K, Burnett JC J, et al. (1993) Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation 88(2): 364-371.
  11. Hoit BD, Shao Y, Tsai LM, Patel R, Gabel M, et al. (1993) Altered left atrial compliance after atrial appendectomy. Influence on left atrial and ventricular filling. Circ Res 72(1): 167-175.
  12. Massoudy P, Beblo S, Raschke P, Zahler S, Becker BF, et al. (1998) Influence of intact left atrial appendage on hemodynamic parameters if isolated guinea pig heart. Eur J Med Res 3(10): 470-474.
  13. Kappagoda CT, Linden RJ, Saunders DA (1972) The effect on heart rate of distending the atrial appendages in dogs. J Physiol 225(3): 705-719.
  14. Blackshear JL, Odell JA (1996) Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61(2): 755-759.
  15. Stoddard MF, Dawkins PR, Prince CR, Ammash NM (1995) Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiography study. J Am Coll Cardiol 25(2): 452-459.
  16. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M (2000) The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 17(6): 718-722.
  17. Shirani J, Alaeddini J (2000) Structural remodelling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol 9(2): 95-101.
  18. Connelly JH, Clubb FJ, Vaughn W, Duncan M (2001) Morphological changes in atrial appendages removed during the maze procedure: a comparison with autopsy controls. Cardiovasc Pathol 10(1): 39-42.
  19. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, et al. (1998) Transoesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvlar atrial fibrillation. J Am Coll Cardiol 31(7): 1622-1626.
  20. Bilge M, Eryonucu B, Güler N, Akdemir I, AÅŸker M (2000) Transesophageal echocardiography assessment of left atrial appendage function in untreated systemic hypertensive patients in sinus rhythm. J Am Soc Echocardiogr 13(4): 271-276.
  21. Ito T, Suwa M, Kobashi A, Yagi H, Hirota Y, et al. (1998) Influence of altered loading conditions on left atrial appendage function in vivo. Am J Cardiol 81(8): 1056-1059.
  22. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N ENgl J Med 361(12): 1139-1151.
  23. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, et al. (2014) Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: a Randomized clinical trial. JAMA 312(19): 1988-1998.
© 2014-2018 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy